MedTrace Logo

Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations

NCT06655064 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-07-14

No results posted yet for this study

Summary

The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time. It will follow subjects and the diagnostic testing and therapy they receive for their prostate cancer.

Subjects will not be administered any medical diagnostic testing or therapy that they would not have normally undergone outside of participation in the registry.

Conditions

  • Prostate Cancer (Adenocarcinoma)

Interventions

OTHER

None- Observational

None- Observational

Sponsors & Collaborators

  • Specialty Networks Research.

    collaborator NETWORK

  • Telix Pharmaceuticals (Innovations) Pty Limited

    lead INDUSTRY

Principal Investigators

  • Aimal Ahmed, MD · Telix Pharmaceuticals

Eligibility

Min Age
21 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-30
Primary Completion
2025-06-17
Completion
2025-06-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06655064 on ClinicalTrials.gov